Back to Search
Start Over
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
- Source :
- Emerging Infectious Diseases; Feb2024, Vol. 30 Issue 2, p262-269, 8p
- Publication Year :
- 2024
-
Abstract
- We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62-$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36-1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49-$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10806040
- Volume :
- 30
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Emerging Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 175183267
- Full Text :
- https://doi.org/10.3201/eid3002.230835